These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 28535786)

  • 1. Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report.
    Wallin A; Kapaki E; Boban M; Engelborghs S; Hermann DM; Huisa B; Jonsson M; Kramberger MG; Lossi L; Malojcic B; Mehrabian S; Merighi A; Mukaetova-Ladinska EB; Paraskevas GP; Popescu BO; Ravid R; Traykov L; Tsivgoulis G; Weinstein G; Korczyn A; Bjerke M; Rosenberg G
    BMC Neurol; 2017 May; 17(1):102. PubMed ID: 28535786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Performance of Cerebrospinal Fluid Neurofilament Light Chain and Soluble Amyloid-β Protein Precursor β in the Subcortical Small Vessel Type of Dementia.
    Axelsson Andrén E; Kettunen P; Bjerke M; Rolstad S; Zetterberg H; Blennow K; Wallin A; Svensson J
    J Alzheimers Dis; 2023; 96(4):1515-1528. PubMed ID: 37980667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein-β in patients with subcortical small-vessel disease.
    Kettunen P; Bjerke M; Eckerström C; Jonsson M; Zetterberg H; Blennow K; Svensson J; Wallin A
    Alzheimers Dement (Amst); 2022; 14(1):e12296. PubMed ID: 35356486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical diagnosis of vascular cognitive impairment associated with subcortical small vessels disease.
    Liakakis G
    Hell J Nucl Med; 2019; 22 Suppl():187-193. PubMed ID: 30877737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease.
    Wallin A; Román GC; Esiri M; Kettunen P; Svensson J; Paraskevas GP; Kapaki E
    J Alzheimers Dis; 2018; 62(3):1417-1441. PubMed ID: 29562536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid Sulfatide Levels Lack Diagnostic Utility in the Subcortical Small Vessel Type of Dementia.
    Svensson J; Blomqvist M; Kettunen P; Eckerström C; Henricsson M; Jonsson M; Bjerke M; Månsson JE; Wallin A
    J Alzheimers Dis; 2021; 82(2):781-790. PubMed ID: 34092632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix Metalloproteinase-Mediated Neuroinflammation in Vascular Cognitive Impairment of the Binswanger Type.
    Rosenberg GA
    Cell Mol Neurobiol; 2016 Mar; 36(2):195-202. PubMed ID: 26993507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.
    Gorelick PB; Scuteri A; Black SE; Decarli C; Greenberg SM; Iadecola C; Launer LJ; Laurent S; Lopez OL; Nyenhuis D; Petersen RC; Schneider JA; Tzourio C; Arnett DK; Bennett DA; Chui HC; Higashida RT; Lindquist R; Nilsson PM; Roman GC; Sellke FW; Seshadri S;
    Stroke; 2011 Sep; 42(9):2672-713. PubMed ID: 21778438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with the Subcortical Small Vessel Type of Dementia Have Disturbed Cardiometabolic Risk Profile.
    Axelsson E; Wallin A; Svensson J
    J Alzheimers Dis; 2020; 73(4):1373-1383. PubMed ID: 31929169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment.
    Toyama K; Spin JM; Tsao PS
    Curr Drug Deliv; 2017 Sep; 14(6):744-757. PubMed ID: 27572324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of biomarkers in subcortical ischaemic vascular disease of the Binswanger type: approach to targeted treatment trials.
    Rosenberg GA; Prestopnik J; Adair JC; Huisa BN; Knoefel J; Caprihan A; Gasparovic C; Thompson J; Erhardt EB; Schrader R
    J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1324-30. PubMed ID: 25618903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
    Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
    CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment.
    Candelario-Jalil E; Thompson J; Taheri S; Grossetete M; Adair JC; Edmonds E; Prestopnik J; Wills J; Rosenberg GA
    Stroke; 2011 May; 42(5):1345-50. PubMed ID: 21454822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in CSF sPDGFRβ level and their association with blood-brain barrier breakdown in Alzheimer's disease with or without small cerebrovascular lesions.
    Lv X; Zhang M; Cheng Z; Wang Q; Wang P; Xie Q; Ni M; Shen Y; Tang Q; Gao F;
    Alzheimers Res Ther; 2023 Mar; 15(1):51. PubMed ID: 36915135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of White Matter Hyperintensities and Related Risk Factors in Vascular Cognitive Impairment: A Review.
    Chen Y; Wang X; Guan L; Wang Y
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.